Caption Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Caption Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.8M	Hold	60,000	–	–	0.14%	145
2026 Q1	$26.8M	Buy	+60,000	New	+$28M	0.16%	136
2025 Q3	–	Sell	-10,300	Closed	-$4.59M	–	2074
2025 Q2	$4.59M	Buy	+10,300	New	+$4.75M	0.05%	430
2024 Q2	–	Sell	-14,000	Closed	-$5.85M	–	1542
2024 Q1	$5.85M	Buy	+14,000	New	+$5.92M	0.09%	272
2023 Q4	–	Sell	-15,000	Closed	-$5.22M	–	1714
2023 Q3	$5.22M	Buy	+15,000	New	+$5.25M	0.08%	310
2022 Q2	–	Sell	-209,900	Closed	-$54.8M	–	1865
2022 Q1	$54.8M	Buy	209,900 +159,900	+320%	+$37.9M	0.66%	17
2021 Q4	$11M	Sell	50,000 -15,000	-23%	-$2.92M	0.12%	205
2021 Q3	$11.8M	Buy	+65,000	New	+$12.7M	0.13%	197
2020 Q2	–	Sell	-27,400	Closed	-$6.52M	–	1198
2020 Q1	$6.52M	Buy	+27,400	New	+$6.29M	0.37%	64
2019 Q3	–	Sell	-25,000	Closed	-$4.58M	–	918
2019 Q2	$4.58M	Hold	25,000	–	–	0.23%	125
2019 Q1	$4.6M	Buy	+25,000	New	+$4.62M	0.25%	119

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Caption Management's VRTX Position: Q2 2026 in Review

Caption Management increased its Vertex Pharmaceuticals (VRTX) stake by 4,600% in Q2 2026, buying an estimated $4.08M and bringing the position to 9,400 shares worth $4.67M. The position accounts for 0.02% of the portfolio, ranked #608.

Caption Management first reported a position in VRTX in Q3 2021 and has held it in 6 quarters since. The position peaked at $12.6M in Q1 2022. 1,760 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Caption Management held 9,400 shares of Vertex Pharmaceuticals worth $4.67M as of Q2 2026.
Caption Management bought 9,200 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.08M.
Vertex Pharmaceuticals made up 0.02% of Caption Management's portfolio in Q2 2026, its #608 holding.
Caption Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
Caption Management's Vertex Pharmaceuticals position peaked at $12.6M in Q1 2022.
1,760 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.